Showing 601-610 of 7509 results for "".
Skincare 2023: Year in Review
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/skincare-2023-year-in-review/24011/Practical Dermatology Co-Chief Medical Editor Joel Schlessinger, MD, shares his favorite skincare products of 2023 – and a few other insights, as well.Prospective Analysis: PRP Post-Mohs; Physician Debt Insights
https://practicaldermatology.com/youngmd-connect/resident-resource-center/propsective-analysis-prp-post-mohs-physician-debt-insights/23038/Ortho Dermatologics NDA, J&J Innovation, Consumer Credit Insights
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-ortho-dermatologics-nda-j-j-innovation-consumer-credit-insights/18395/Two-thirds of prospective patients say they would be more likely to book a procedure if they were aware of financing options. More than three-quarters of prospective patients are unaware of financing options, according to a recent survey by Zalea. In conjunction with Johnson & Johnson Consumer,Moisturizers for Skin Diseases: New Insights
https://practicaldermatology.com/topics/atopic-dermatitis/moisturizers-for-skin-diseases-new-insights/22977/Prednisone-induced DRESS Syndrome
https://practicaldermatology.com/topics/general-topics/prednisone-induced-dress-syndrome/21572/This unusual reaction was resolved with a switch to a Group C steroid.COVID-19 Impact: Navigating Clinical Research
https://practicaldermatology.com/series/dermatology-dispatches/covid-19-impact-navigating-clinical-research/19771/Conducting clinical research studies is challenging as the majority of Americans are under stay-at-home orders for the forseeable future due to the COVID-19 pandemic, says Todd E. Schlesinger, MD. He suggests trialists do their best to say in contact with clinical research organizations, sponsors, aFDA Approvals, Acne Insights, EPI Gets Cloderm
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-approvals-acne-insights-epi-gets-cloderm/18230/In a flurry of approvals, FDA gives the nod to Almirall's Seysara (sarecycline), Ortho Dermatologics' Bryhali (halobetasol propionate, 0.01%) Lotion, Paratek Pharmaceuticals' Nuzyra (omadacycline), and Regeneron's Libtayo (cemiplimab). Research shows top earners across various fields in the US mayConjunctival Squamous Cell Carcinoma: A Video-Illustration of a Surgical Approach
https://practicaldermatology.com/youngmd-connect/resident-resource-center/conjunctival-squamous-cell-carcinoma-a-video-illustration-of-a-surgical-approach/23378/DermWireTV: AcneAlly Launches, Rosacea Insights, MC2/EPI Collaboration
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-acneally-launches-rosacea-insights-mc2epi-collaboration/19849/Dennis Porto, MD and Riyaz Farhaad, MD have launched AcneAlly.com, an online service that allows patients access to a board certified dermatologist and a standardized approach to assessment and long-term monitoring. Julie Harper, MD discusses findings from “Beyond the visible: Rosacea and psoriasisThin Melanomas: When is SLN Biopsy Indicated?
https://practicaldermatology.com/topics/skin-cancer-photoprotection/thin-melanomas-when-is-sln-biopsy-indicated/20805/New research offers additional evidence that mitotic rate may have a role in clinical decision-making.